免疫介导炎症性疾病的新型治疗:从类风湿关节炎等疾病中获得的启示
本综述探讨了免疫介导炎症性疾病(IMID)的新型治疗策略及其对病理生物学的启示。文章回顾了靶向Th17轴、I/II型干扰素、细胞黏附、JAK、B细胞和调节性T细胞的新型生物制剂及小分子药物,并介绍了双特异性抗体的开发。这些疗法不仅为IMID提供了更优治疗,也为研究其免疫病理基础提供了独特机会。
要点
- 靶向Th17轴(IL-17、IL-17R、IL-12/23p40、IL-23p19)的生物制剂是IMID治疗的重要方向。
- JAK抑制剂(第一代pan-JAK和第二代选择性JAK)在IMID治疗中已有开发和应用。
- 双特异性抗体等生物技术进展为IMID治疗提供了新策略。
核心结论
- 过去三十年靶向免疫和炎症反应特定成分的能力取得显著进步,为IMID提供了更优治疗并提供了研究其免疫病理基础的机会。
研究设计与样本
- 这是一篇综述,探讨了IMID的最新治疗方法及其提供的病理生物学见解。
主要发现
- 综述涵盖了靶向Th17轴的新型生物制剂,包括针对IL-17、IL-17R、IL-12/23p40和IL-23p19的药物。
- 综述概述了针对I型和II型干扰素的生物制剂,以及干扰淋巴细胞招募的细胞黏附过程的新兴策略。
- 综述总结了JAK抑制剂在IMID治疗中的开发和应用,以及靶向B细胞的新生物制剂和调节性T细胞调节的新策略。
- 综述探讨了双特异性抗体等最新生物技术进展及其在IMID治疗中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. As well as providing superior treatments for immune-mediated inflammatory diseases (IMIDs), such therapies also offer unrivalled opportunities to study the underlying immunopathological basis of these conditions.In this review, we explore recent approaches to the treatment of IMIDs and the insights to pathobiology that they provide. We review novel biologic agents targeting the T-helper 17 axis, including therapies directed towards interleukin (IL)-17 (secukinumab, ixekizumab, bimekizumab), IL-17R (brodalumab), IL-12/23p40 (ustekinumab, briakinumab) and IL-23p19 (guselkumab, tildrakizumab, brazikumab, risankizumab, mirikizumab). We also present an overview of biologics active against type I and II interferons, including sifalumumab, rontalizumab, anifrolumab and fontolizumab. Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, including both integrin blockade (natalizumab, vedolizumab, etrolizumab) and sphingosine-1-phosphate receptor inhibition (fingolimod, ozanimod). We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib). New biologics targeting B-cells (including ocrelizumab, veltuzumab, tabalumab and atacicept) and the development of novel strategies for regulatory T-cell modulation (including low-dose IL-2 therapy and Tregitopes) are also discussed. Finally, we explore recent biotechnological advances such as the development of bispecific antibodies (ABT-122, COVA322), and their application to the treatment of IMIDs.
引用
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2017. PMID: 28765121. doi:10.1136/annrheumdis-2017-211555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。